Clinical Trial Update: Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma [Phase 3]

View source ↗

Summary

Phase 3 safety and tolerability update for omalizumab in adults and adolescents with severe allergic asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: Novartis | Conditions: Asthma | Phase 3 | Status: COMPLETED